Online citations, reference lists, and bibliographies.

Hypochlorhydria From Short-term Omeprazole Treatment Does Not Inhibit Intestinal Absorption Of Calcium, Phosphorus, Magnesium Or Zinc From Food In Humans.

C. Serfaty-Lacrosniere, R. Wood, D. Voytko, J. Saltzman, M. Pedrosa, T. Sepe, R. R. Russell
Published 1995 · Chemistry, Medicine
Cite This
Download PDF
Analyze on Scholarcy
OBJECTIVE Low gastric pH is generally believed to be an important factor in intestinal mineral absorption. Thus, hypochlorhydria could be an important risk factor for mineral malabsorption and the development of marginal mineral status. We studied whether the hypochlorhydria associated with treatment with the anti-ulcer medication omeprazole, a potent gastric proton pump inhibition, would affect intestinal calcium, phosphorus, magnesium, or zinc absorption from food. METHODS Thirteen normal, healthy adults were assigned to either a control group (n = 5) receiving no drug treatment or an omeprazole treatment group (n = 8) to produce increased gastric pH. Omeprazole treatment of normal volunteers resulted in a significant change in postprandial gastric pH (pH 6.4 +/- 0.3 vs. 3.6 +/- 0.5 in control subjects, p < 0.01) and baseline fasting pH (pH 5.8 +/- 0.5 vs. pH 1.8 +/- 0.3 in controls, p < 0.01) after an overnight fast. Net mineral absorption from a standard test meal was measured using a whole gut lavage technique. Mineral absorption was measured twice in each subject, once with 120 mL of 0.1 mol/liter hydrochloric acid and a second time with 120 mL of distilled water alone. RESULTS We found that despite marked changes in gastric pH due to drug treatment or administration of exogenous HCl, no change in the intestinal absorption of calcium, phosphorus, magnesium or zinc from a standard test meal was evident. CONCLUSIONS These findings suggest that changing the gastric pH alone does not modify the net intestinal absorption of several minerals from food. Therefore, it is unlikely that moderate hypochlorhydria resulting from short-term omeprazole treatment substantially increases the risk for developing calcium, phosphorus, magnesium, or zinc deficiencies due to mineral malabsorption.

This paper is referenced by
Proton pump inhibitors are now massively utilized medications worldwide but their H + ,K + -ATPase and non-H + ,K + -ATPase mediated side effects are poorly appreciated
J. Mullin (2009)
Proton Pump Inhibitors: Risks and Rewards and Emerging Consequences to the Gut Microbiome.
Amandeep Singh (2018)
Magnesium bioavailability from mineral water. A study in adult men
Maximilian Verhas (2002)
Nutrizione e prevenzione del rischio di osteoporosi
Alessandro Medina Pinto (2009)
Proton pump inhibitors have no measurable effect on calcium and bone metabolism in healthy young males: a prospective matched controlled study.
Ala I Sharara (2013)
Indications and safety of proton pump inhibitor drug use in patients with cancer
George Triadafilopoulos (2013)
Metabolic Bone Disease in Gastrointestinal Disorders
Ann Cranney (2010)
Gastrointestinal Tract and the Control of Bone Mass
Thorsten Schinke (2013)
Adverse Effects of Proton Pump Inhibitors—Evidence and Plausibility
R. Fossmark (2019)
Peter J. Kahrilas (2013)
Zinc and gastrointestinal disease.
Sonja M. Skrovanek (2014)
Gastric acid, calcium absorption, and their impact on bone health.
Sascha Kopic (2013)
The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study
L-A. Fraser (2012)
Medical therapy of GERD and NERD The severity of symptoms does not correlate with the presence or with severity of subtypes of GERD (
Smout AJPM (2012)
Gastric Acid-Related Diseases: Focus on Esomeprazole
Bandar Aljudaibi (2010)
Ostéoporose et inhibiteurs de pompe à protons
Christian Roux (2011)
Effets indésirables des inhibiteurs de la pompe à proton : faut-il craindre de les prescrire au long cours ?
Lucien Roulet (2012)
16. Metabolic Bone Disease in Gastrointestinal Disorders
Ann Cranney (2010)
Proton pump inhibitors and severe hypomagnesaemia
T. F. Cundy (2011)
Severe hypomagnesemia refractory to oral supplementation associated to omeprazole treatment
Franchini (2017)
The Risks and Benefits of Long-term Use of Proton Pump Inhibitors: Expert Review and Best Practice Advice From the American Gastroenterological Association.
Daniel E Freedberg (2017)
Are Proton Pump Inhibitors Suitable Medicines to Prevent Gastrointestinal Events Due to Non-steroidal Anti-inflammatory Drugs?
Katsuhiro Toda (2018)
Hip fracture risk in patients with a diagnosis of pernicious anemia.
N. Merriman (2010)
Omeprazole enhances the colonic expression of the Mg2+ transporter TRPM6
Anke L L Lameris (2013)
Contemporary view of the clinical relevance of magnesium homeostasis
John Ayuk (2014)
Population-based studies on risk of fracture in patients with neurological disorders
Sander Pouwels (2014)
Evidence of Drug–Nutrient Interactions with Chronic Use of Commonly Prescribed Medications: An Update
Emily S Mohn (2018)
Effects of Non-Steroidal Anti-Inflammatory Drugs on the Gastrointestinal and Cardiovascular System
G Masclee (2016)
Adverse Effects of Long-Term Proton Pump Inhibitor Therapy
Edward Sheen (2010)
Proton pump inhibitors in rheumatic diseases: clinical practice, drug interactions, bone fractures and risk of infections.
Antonella Laria (2011)
O czym warto pamiętać, stosując przewlekle inhibitory pompy protonowej?
Tomasz Wocial (2013)
Original Investigation Proton Pump Inhibitors and Hypomagnesemia in the General Population: A Population-Based Cohort Study
Mark Eijgelsheim (2015)
See more
Semantic Scholar Logo Some data provided by SemanticScholar